DRKS00027049已完成不适用
Response to SARS-CoV-2 (COVID-19) vaccines in patients receiving B-cell modulating antibodies for renal immune disease - RENCOVAC
Medizinische Klinik IV, Universitätsklinikum Freiburg0 个研究点目标入组 34 人开始时间: 2021年10月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Age > 18 years
- •- Diagnosis of renal immunological disease
- •- Previous or ongoing antibody treatment with Rituximab
- •- Full vaccination with either mRNA-based (BNT162b2, mRNA-1273), or Vector-based (ChAdOx1, Ad26.COV2.S) SARS-CoV-2 vaccines
排除标准
- •Previous COVID-19-disease, use of antimetabolite drugs, such as Mycophenolate Mofetil, Azathioprine, Methotrexate two months prior to vaccination.
研究者
相似试验
进行中（未招募）
1 期
Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 .Renal failure stage 4 and 5.EUCTR2021-000988-68-SERegion Stockholm60
尚未招募
不适用
COVID-19 VaccinAtion in patients with chronic Kidney disease in New Zealand (C-VAK NZ study)Kidney TransplantDialysisCovid-19Renal and Urogenital - Kidney diseaseInfection - Other infectious diseasesACTRN12621000460808Auckland District Health Board600
尚未招募
不适用
Response rate to SARS-CoV-2 (COVID-19) vaccine in dialysis patients.JPRN-UMIN000043368agasaki University110
进行中（未招募）
1 期
Substudy Responses to Covid-19 vaccines in research Clinical picture, immunology, genetics and pathogenesis of COVID-19 infectiooneEUCTR2021-004016-26-FIMeilahti Vaccine Research Center - Helsinki University Hospital1,000
进行中（未招募）
1 期
Response to corona vaccination in patients with primary Sjögren's syndromePrimary Sjögren's syndromeEUCTR2021-001414-10-NLniversity Medical Center Groningen180